Regulatory Hurdles and Ethical Concerns Beset FDA Oversight of AI/ML Devices

Key Takeaways

• The FDA struggles with regulating rapidly advancing AI/ML technologies in medical devices, leading to regulatory gaps and challenges.
• Class I and II devices often bypass rigorous premarket approval, while class III high-risk devices undergo thorough scrutiny.
• Many devices with embedded AI/ML are not classified as such, leading to inconsistent regulatory oversight and potential safety concerns.
• Studies reveal racial and gender biases in AI-driven healthcare decisions, highlighting ethical concerns and the need for transparency.
• Transparency and validation of AI/ML devices are critical issues, with many lacking prospective validation and publicly available clinical data.

An ACCP speaker explains that the FDA faces a multitude of challenges.

Today's Sponsors

Today's Sponsor